Longeveron (LGVN) – Company Press Releases
-
Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering
-
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
-
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s As
-
Longeveron Announces Closing of $5.2 Million Public Offering
-
Longeveron Announces Pricing of $5.25 Million Public Offering
-
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
-
Longeveron Announces 1-for-10 Reverse Stock Split
-
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
-
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
-
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™
-
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease
-
ExThera Medical Taps Current Board Member and Top Finance Executive to Take the Helm
-
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.
-
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association
-
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
-
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
-
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s
-
Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
-
Longeveron Issues Letter to Stockholders
-
IBN Coverage Initiated for Longeveron Inc.
-
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association
-
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
-
Presenting on the Emerging Growth Conference on September 6 and 7 Register Now
-
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
-
Longeveron Rights Offering Subscription Period Begins
-
Longeveron Rights Offering Declared Effective and Calendar Finalized
-
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
-
Longeveron Announces Pricing for Rights Offering and Expected Calendar
-
Longeveron Reports Second Quarter 2023 Results and Provides Corporate Update
-
Longeveron Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome
-
Presenting on the Emerging Growth Conference on August 9 & 10 Register Now
-
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
-
Longeveron Appoints Lisa Locklear as Chief Financial Officer
-
Longeveron Appoints Dr. Nataliya Agafonova as Chief Medical Officer
-
Longeveron Congratulates Co-Founder and Chairman Dr. Joshua Hare on Induction as Fellow of National Academy of Inventors
-
Longeveron Files Registration Statement for Rights Offering
-
Longeveron Welcomes Three New Prominent Board Members
-
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
-
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
-
Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023
-
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
-
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
-
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
-
Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal
Back to LGVN Stock Lookup
